← All stocks

Vertex Pharmaceuticals

VRTX Net selling
CIK 0000875320 #469 in the set updated 17 Sep 2026
Bought (120 mo)
$14.03M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$1.33B
$217.70M on a plan · $847.16M straight out of an exercise
Sold at will
$264.28M
752 of 1885 sales
Net
−$1.32B
−$250.25M against sales at will

By person

36 insiders · 1,897 transactions
31.8×

Reshma Kewalramani holds 31.8 times base salary in stock. $51.01M of shares against $1.60M in salary for 2025.

Salary from the company's own proxy. The shares are what Reshma Kewalramani last reported holding, valued at $519.00, the price Common Stock was last bought or sold at on the open market here, on 2 Jul 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
LEIDEN JEFFREY M
Executive Chairman
$498.46M (156) scheduled
−$498.46M
34,797
$18.06M
−86.8%
Sachdev Amit
EVP Chief Patient & Ext Af Off
$128.86M (187) scheduled
−$128.86M
66,512
$34.52M
−18.1%
Arbuckle Stuart A
EVP, COO
$114.46M (206) scheduled
−$114.46M
97,921
$50.82M
−39.9%
ALTSHULER DAVID
EVP, Chief Scientific Officer
$88.19M (209) scheduled
−$88.19M
34,477
$17.89M
−64.0%
Kewalramani Reshma
CEO & President
$5.85M (4)
$80.66M (75) scheduled
−$74.81M
98,278
$51.01M
+964.3%
SMITH IAN F
EVP, COO
$67.00M (49) scheduled
−$67.00M
46,699
$24.24M
−60.3%
Parini Michael
EVP, Chief Adm, Leg & BD Off
$45.43M (168) scheduled
−$45.43M
30,837
$16.00M
+109.9%
Silva Paul M
SVP & Chief Accounting Officer
$35.17M (136) scheduled
−$35.17M
9,884
$5.13M
−32.2%
SACHS BRUCE I
Director
$8.18M (6)
$38.25M (28) scheduled
−$30.08M
39,000
$20.24M
+175.6%
Bozic Carmen
EVP and CMO
$30.00M (22) scheduled
−$30.00M
15,337
$7.96M
+631.4%
Chodakewitz Jeffrey
EVP
$27.57M (71) scheduled
−$27.57M
69,663
$36.16M
−38.1%
WAGNER CHARLES F JR
EVP, CO & FO
$24.25M (48) scheduled
−$24.25M
47,042
$24.41M
+6,535%
Tatsis Ourania
EVP, Chief Reg. & Quality Off.
$21.35M (93) scheduled
−$21.35M
53,572
$27.80M
+529.0%
Lee Yuchun
Director
$18.69M (138) scheduled
−$18.69M
1,875
$973.13K
−52.9%
MCGLYNN MARGARET G
Director
$14.52M (14) scheduled
−$14.52M
178
$92.38K
−95.7%
Kearney Terrence C
Director
$13.99M (7) scheduled
−$13.99M
6,536
$3.39M
+47.2%
Bhatia Sangeeta N.
Director
$12.67M (63) scheduled
−$12.67M
4,924
$2.56M
+67.4%
Atkinson Edward Morrow III
EVP, Chief Technical Ops. Off.
$11.60M (13) scheduled
−$11.60M
18,432
$9.57M
+32.8%
YOUNG WILLIAM D
Director
$10.94M (8) scheduled
−$10.94M
9,311
$4.83M
+216.6%
Sanna Bastiano
EVP, Cell & Genetic Therapies
$10.54M (63) scheduled
−$10.54M
32,038
$16.63M
+49.6%
BOGER JOSHUA S
Director
$9.22M (54) scheduled
−$9.22M
284,088
$147.44M
+0.8%
Biller Jonathan
EVP and Chief Legal Officer
$7.81M (12) scheduled
−$7.81M
13,659
$7.09M
McKechnie Duncan
EVP, Chief Commercial Officer
$5.66M (5) scheduled
−$5.66M
11,001
$5.71M
−32.1%
Ambrose Kristen
SVP & Chief Accounting Officer
$4.93M (19) scheduled
−$4.93M
11,624
$6.03M
+733.9%
Liu Joy
EVP and Chief Legal Officer
$4.73M (31)
−$4.73M
19,131
$9.93M
−31.2%
Bunnage Mark E.
EVP, Chief Scientific Officer
$3.00M (5) scheduled
−$3.00M
7,284
$3.78M
−54.7%
CARNEY LLOYD
Director
$865.41K (3)
−$865.41K
6,315
$3.28M
Graney Thomas
Chief Financial Officer
$324.44K (2)
−$324.44K
12,430
$6.45M
+5,628%
ULLIAN ELAINE
Director
12,195
$6.33M
+48.6%
van Grunsven Jasper
EVP, CP and NPPO
8,682
$4.51M
Garber Alan M
Director
7,344
$3.81M
MCKENZIE DIANA
Director
2,378
$1.23M
Thornberry Nancy
Director
2,109
$1.09M
Upadhyay Suketu
Director
1,558
$808.60K
Schneider Jennifer
Director
1,394
$723.49K
Lagarde Michel
Director
1,132
$587.51K

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Insider
Date
Role
Action
Shares
Price
Amount
Sachdev Amit
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
4,237
$471.43
$2.00M
Sachdev Amit
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
11,712
$470.54
$5.51M
Sachdev Amit
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
7,241
$469.61
$3.40M
Sachdev Amit
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
19,662
$468.57
$9.21M
Sachdev Amit
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
10,263
$467.75
$4.80M
Sachdev Amit
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
1,848
$465.80
$860.80K
Sachdev Amit
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
2,730
$465.05
$1.27M
Sachdev Amit
19 Feb 2026
EVP Chief Patient & Ext Af Off
Sold after exercise
920
$463.91
$426.80K
WAGNER CHARLES F JR
6 Jan 2026
EVP, CO & FO
Sold after exercise
9,532
$461.00
$4.39M
LEIDEN JEFFREY M
3 Dec 2025
Executive Chairman
Sold after exercise
2,070
$455.22
$942.31K
LEIDEN JEFFREY M
3 Dec 2025
Executive Chairman
Sold after exercise
10,360
$453.34
$4.70M
LEIDEN JEFFREY M
3 Dec 2025
Executive Chairman
Sold after exercise
15,681
$452.20
$7.09M
LEIDEN JEFFREY M
3 Dec 2025
Executive Chairman
Sold after exercise
5,809
$451.20
$2.62M
LEIDEN JEFFREY M
3 Dec 2025
Executive Chairman
Sold after exercise
5,880
$449.84
$2.65M
LEIDEN JEFFREY M
3 Dec 2025
Executive Chairman
Sold after exercise
2,320
$448.78
$1.04M
LEIDEN JEFFREY M
3 Dec 2025
Executive Chairman
Sold after exercise
1,152
$447.05
$515.00K
LEIDEN JEFFREY M
3 Dec 2025
Executive Chairman
Sold after exercise
7,899
$445.56
$3.52M
LEIDEN JEFFREY M
3 Dec 2025
Executive Chairman
Sold after exercise
4,352
$444.36
$1.93M
LEIDEN JEFFREY M
3 Dec 2025
Executive Chairman
Sold after exercise
2,469
$443.21
$1.09M
LEIDEN JEFFREY M
3 Dec 2025
Executive Chairman
Sold after exercise
1,320
$441.26
$582.46K
LEIDEN JEFFREY M
3 Dec 2025
Executive Chairman
Sold after exercise
4,469
$440.40
$1.97M
LEIDEN JEFFREY M
14 Nov 2025
Executive Chairman
Sold after exercise
40
$442.00
$17.68K
LEIDEN JEFFREY M
14 Nov 2025
Executive Chairman
Sold after exercise
21,330
$441.35
$9.41M
LEIDEN JEFFREY M
14 Nov 2025
Executive Chairman
Sold after exercise
32,234
$440.30
$14.19M
LEIDEN JEFFREY M
13 Nov 2025
Executive Chairman
Sold after exercise
1,160
$441.05
$511.62K
LEIDEN JEFFREY M
13 Nov 2025
Executive Chairman
Sold after exercise
18,528
$440.22
$8.16M
Bhatia Sangeeta N.
30 Aug 2024
Director
Sold after exercise
646
$500.00
$323.00K
Bhatia Sangeeta N.
8 Aug 2024
Director
Sold after exercise
1,292
$466.29
$602.45K
SACHS BRUCE I
1 Aug 2024
Director
Sold after exercise
5,295
$508.00
$2.69M
Kewalramani Reshma
24 May 2024
CEO & President
Sold after exercise
1,565
$457.00
$715.21K
SACHS BRUCE I
22 May 2024
Director
Sold after exercise
7,073
$448.00
$3.17M
Kewalramani Reshma
15 Dec 2023
CEO & President
Sold after exercise
17,135
$407.00
$6.97M
Arbuckle Stuart A
13 Dec 2023
EVP, COO
Sold after exercise
8,603
$399.00
$3.43M
SACHS BRUCE I
6 Nov 2023
Director
Sold after exercise
11,250
$385.00
$4.33M
Kearney Terrence C
10 Aug 2023
Director
Sold after exercise
10,000
$350.00
$3.50M
SACHS BRUCE I
17 Jul 2023
Director
Sold after exercise
3,842
$357.29
$1.37M
SACHS BRUCE I
17 Jul 2023
Director
Sold after exercise
5,711
$356.75
$2.04M
SACHS BRUCE I
17 Jul 2023
Director
Sold after exercise
1,697
$355.54
$603.35K
Arbuckle Stuart A
15 Jun 2023
EVP, COO
Sold after exercise
8,603
$349.00
$3.00M
SACHS BRUCE I
12 Apr 2023
Director
Sold after exercise
8,026
$327.48
$2.63M
SACHS BRUCE I
12 Apr 2023
Director
Sold after exercise
10,357
$326.46
$3.38M
SACHS BRUCE I
12 Apr 2023
Director
Sold after exercise
2,917
$325.65
$949.92K
Showing 250 of 1,897 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 1,077
Amendments (4/A) skipped 3
Filings about a different issuer 2
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 213
Sales straight out of an exercise 920
Sales at will 752
Transactions with no price 0
Shares from compensation/vesting 8,056,182
Sales filed before the plan box existed 752
History held since 2 Sep 2016